|
|
|
|
| Advertisement |
 |
|
|
| Top Story |
 |
|
Showdown Nears for European Research Incentives |
In the coming weeks, the EU will decide if the degree of protection offered to drug firms by research incentives such as the supplementary protection certificate (SPC) are really in the interests of patients and society. Reflector reports
... /Read more/ |
|
|
| Outcomes-Based Healthcare |
 |
|
Risk Sharing, Italian Style |
Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale
... /Read more/ |
|
|
| Translational Science |
 |
|
BMS and Biomarker Research |
Saurabh Saha, SVP and Global Head of Translational Medicine at Bristol Myers-Squibb, shares his perspectives on the current biomarker landscape, the role of translational medicine, and how BMS is working to advance biomarker research across their R&D portfolio
... /Read more/ |
|
|
|
|
|
| Industry update |
| //Rentschler Biopharma (Laupheim, Germany) appointed Federico Pollano as Senior Vice President, Business Development. //Helsinn (Lugano, Switzerland) appointed Paul Rittman as Chief Executive Officer of its U.S. subsidiary, Helsinn Therapeutics, replacing William Mann, who stepped down on February 28, 2018. //Bone Therapeutics (Gosselies, Belgium) appointed Jean Stéphenne as Chairman of the Board of Directors, replacing Steve Swinson, who is stepping down. //Apitope (Hasselt, Belgium, and Chepstow, UK) announced the appointment of William Jenkins, M.D., as independent non-executive director to its Board of Directors.//Forendo Pharma (Turku, Finland) appointed David Colpman as a non-executive director to its Board of Directors. //Metrion Biosciences Limited (Cambridge, UK) appointed Dr. Barry Kenny and Dr. Andrew Southan to its Board of Directors.//
|
|
|
|
